All Stories

  1. Comparison of initial drug treatment of incident COPD patients with German treatment guidelines
  2. Risk of future exacerbations among COPD patients – a real-world register-based cohort study (AvoidEx)
  3. Diagnosing Alpha-1-Antitrypsin Deficiency Using A PCR/Luminescence-Based Technology
  4. Adherence To Respiratory And Nonrespiratory Medication In Patients With COPD: Results Of The German COSYCONET Cohort
  5. Umeclidinium/vilanterol in preventing clinically important deterioration (CID) in COPD and impact of baseline disease severity: the EMAX trial
  6. The frequent exacerbator in real-life: an analysis of the DACCORD study
  7. Prevalence of cardiac comorbidities, and their underdetection and contribution to exertional symptoms in COPD: results from the COSYCONET cohort
  8. Determinants of healthcare utilization and costs in COPD patients: first longitudinal results from the German COPD cohort COSYCONET
  9. Personalized medicine for patients with COPD: where are we?
  10. Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population
  11. Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort
  12. COPD as a risk factor of the complications in lower limb arthroplasty: a patient-matched study
  13. Influence of body mass on predicted values of static hyperinflation in COPD
  14. Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study
  15. Health status in patients with COPD treated with roflumilast: two large noninterventional real-life studies: DINO and DACOTA
  16. COPD exacerbation rates with IND/GLY
  17. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study
  18. The contribution of symptoms and comorbidities to the economic impact of COPD: an analysis of the German COSYCONET cohort
  19. Perception of symptoms and quality of life – comparison of patients’ and physicians’ views in the COPD MIRROR study
  20. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
  21. Deterioration of quality of life is associated with the exacerbation frequency in individuals with alpha-1-antitrypsin deficiency – analysis from the German Registry
  22. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary
  23. “Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD
  24. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary
  25. Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis
  26. Efficacy and safety of aclidinium/formoterolversussalmeterol/fluticasone: a phase 3 COPD study
  27. A year in the life of German patients with COPD: the DACCORD observational study
  28. Highlights and hot topics in the management of COPD: where are we heading?
  29. The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency